Biokey International Inc (BKYI)

[dws]

BIO-key International (BKYI) is hosting a small investor open house and technology demonstration led by CEO Mike DePasquale and other executives at the company's Wall, NJ headquarters.

The informal program will review BKYI’s business strategy and goals, feature demonstrations of BIO-key’s technology and all attendees will receive a complimentary fingerprint reader. More details on BIO-key are provided below.

After many years, the dawn of biometric authentication now seems to be here:


Inline image 1


Who: Current and potential investors in BIO-key International (OTCQB: BKYI)

When: Tuesday, June 28th at 3:00 pm ET - program will last approximately an hour.

Where: BIO-key's Corporate Headquarters, 3349 Highway 138 Building A, Suite E, Wall, NJ 07719 (https://goo.gl/maps/JUj5paQbSA12)

RSVP Required: Please RSVP ASAP to [e-mail] or 212 924 2800

Best,


Bill Jones Catalyst Global - IR

212 924 9800

[e-mail]





BIO-key (BKYI) Overview:

. - Leader in fingerprint biometric software and hardware technologies for credentialing, identity and access management solutions.

- Impressive customer base: the FBI; Cleveland Clinic; NCR and LexisNexis.

- Marketing partnerships with IBM, Oracle, Computer Associates, NCR, Allscripts, IDCC and Microsoft (as a Windows 10 Launch Partner).

- Strong technology and patent position; Patents for securely transmitting biometric data to the cloud and sending back a response.
- BIO-key has extended its software leadership into the fingerprint reader market - developing a line of high quality, low cost readers.

- BKYI readers enable enterprises to cost effectively deploy the innate biometric sign-on capabilities of Microsoft’s Windows 10.

- The fingerprint sensor-enabled device market is expected to more than quadruple by 2020.

- BKYI expects impressive revenue growth in 2016 both from existing clients and partners as well as significant new opportunities in the enterprise and consumer markets in Asia. Guidance is for revenues of $7.0M to $9.5M in 2016, up from $5.3M in 2015.

- BIO-key also believes 2016 could represent an inflection point in moving into profitability. Guidance is for break-even around $7.0-$7.5M in revenues.

- BIO-key is well capitalized with ~$5 million of working capital following a recent strategic capital raise.

- BKYI’s market cap is $37 million, (adjusted for ~132M diluted shares out., assuming conversion of preferred stock).


Best,

Bill